Early initiation of moderate-intensity aerobic exercise reduced pain compared with standard care among postmenopausal women who received aromatase inhibitors.

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment.

Q4 2024 Earnings Call Transcript March 31, 2025 Celcuity Inc. misses on earnings expectations. Reported EPS is $-0.85 EPS, ...

GP with an interest in women’s health Dr Laura Patterson discusses key issues in identifying and managing symptoms of ...

Good afternoon, ladies and gentlemen, and welcome to the Celcuity fourth quarter and full year 2024 financial results webcast conference call. (Operator Instructions) I would now like to turn the ...

with a CDK4/6 inhibitor and an aromatase inhibitor. We recognize that the treatment landscape for these second and third-line patients is evolving as a number of investigational therapies are ...

such as injectable fulvestrant – sold by AZ as Faslodex and the only SERD approved for breast cancer – or aromatase inhibitors like letrozole, anastrozole, or exemestane. For the overall group ...